Search for content, post, videos

Novo Nordisk has submitted two new NDAs to the FDA

Mads Krogsgaard Thomsen

The company announced the submission of two New Drug Applications (NDAs) for oral semaglutide, a once-daily glucagon-like peptide-1 (GLP-1) analogue in a tablet, as well as a supplemental NDA (sNDA) for once-weekly Ozempic (semaglutide).

Seeking approval for an indication for the treatment of adults with type 2 diabetes

An NDA was submitted for oral semaglutide seeking approval for an indication for the treatment of adults with type 2 diabetes. A priority review voucher (PRV) has been applied to the NDA, leading to an anticipated review time of six months from the submission date, according to standard FDA review timelines.

The submission for oral semaglutide for the treatment of glycaemic control in adults with type 2 diabetes is based on the results from 10 PIONEER clinical trials, which included 9,543 adults with type 2 diabetes. In the PIONEER programme, people treated with oral semaglutide achieved greater blood glucose reductions compared to sitagliptin, empagliflozin, liraglutide and placebo. In addition, oral semaglutide demonstrated greater reductions in mean body weight vs most comparators. Across the PIONEER trials, oral semaglutide had a safe and well-tolerated profile, with the most common adverse event being nausea.

Seeking approval for a cardiovascular risk reduction indication

A second NDA was submitted for oral semaglutide seeking approval for a cardiovascular (CV) risk reduction indication in adults with type 2 diabetes. The NDA for an oral semaglutide cardiovascular risk reduction indication has an anticipated 10-month review time from the submission date, according to standard FDA review timelines.

An sNDA for Ozempic

Finally, an sNDA was submitted for Ozempic for a cardiovascular risk reduction indication in adults with type 2 diabetes. The sNDA for an Ozempic cardiovascular risk reduction indication has an anticipated 10-month review time from the submission date, according to standard FDA review timelines.

The applications for the oral semaglutide and Ozempic cardiovascular risk reduction indications are based on the results of two cardiovascular outcomes trials (CVOTs) evaluating the effects of adding semaglutide or placebo to standard of care on the risk of cardiovascular events; PIONEER 6 with oral semaglutide and SUSTAIN 6 with Ozempic.

Improve the treatment of adults living with type 2 diabetes

“Achieving glycaemic control and managing cardiovascular risk remains a challenge for many adults living with type 2 diabetes,” said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. “We are excited about the regulatory filings of the first GLP-1 receptor agonist in a tablet, as we believe oral semaglutide has the potential to further improve the treatment of adults living with type 2 diabetes.”

Photo of Mads Krogsgaard Thomsen: Novo Nordisk